Gene Silencing/Gene Editing | Gene News GenomeWeb

Gene Silencing/Gene Editing

The Atlanta-based firm seeks to develop antiviral genome-targeting therapies for HBV and HPV using CRISPR/Cas9.

The gene editing firm has sold all 5.9 million shares offered to the public as well as 885,000 shares in the fully exercised over-allotment option to the underwriters.

For several reasons, scientists, as well as gene editing therapy company Editas, think that the first clinical trials for CRISPR-based cures will be for hereditary eye diseases.

The Cambridge, Massachusetts-based gene editing firm will offer 5.9 million shares of common stock, for a total of $94.4 million.

The research project, led by Kathy Niakan of the Francis Crick Institute, will involve editing several genes thought to be important to embryo development.

Hybrid promoter and recombinant vector comprising the same
Switchable gRNAs comprising apatamers
Methods and compositions for selecting siRNA of improved functionality
miRNA fingerprint in the diagnosis of diseases
Methods for identifying a target site of a Cas9 nuclease
Compositions and methods for inhibiting expression of the ALAS1 gene

Editas Files for IPO

In Nature this week: weighting scheme increases GWAS power, and more.

Marc Tessier-Lavigne is to be the next president of Stanford University.

Walgreens has given Theranos 30 days to fix its lab issues, the Wall Street Journal reports.

Journals and research funding agencies pledge to enable the sharing of Zika virus research.